news

Orally disintegrating tablets market driven by CNS disease treatments

0
SHARES

The preference for orally disintegrating tablets (ODT) to treat CNS-related diseases will increase the market from $12bn in 2018, with a solid growth rate.

The global orally disintegrating tablets (ODTs) market was valued at nearly $12 billion in 2018 and will exhibit a solid compound annual growth rate (CAGR) during the forecast period 2019-2029, a new report has said.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

This is due to the growing preference for using ODTs to treat diseases related to the central nervous system (CNS), gastrointestinal (GI), cardiovascular disorders and allergies, explained the report by Persistence Market Research.

CNS diseases remain the primary area of application for ODTs, the report said, with researchers and healthcare providers increasingly focusing on medical conditions such as encephalitis, autism, Alzheimer’s disease, schizophrenia, depressive disorders and others to increase the application of ODTs.

The easy disintegration of ODTs in saliva within a few seconds and the accuracy of dose as compared to liquid forms and chewable tablets are also expected to increase the adoption of ODTs in diseases such as ulcers of the throat, the report continued.

Furthermore, due to consumers facing swallowing problems, the bitter taste of drugs and patient in-compliance, manufacturers are reportedly focusing to improve drug formulations to help them gain an edge in terms of innovation, which further aids in the growth of this market.

Share via
Share via